Stock Events

Stock Events

Kalytera Therapeutics 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Profitable
2015
2016
2017
2018
2019
2020
0Revenue
4.05MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a major player in the pharmaceutical industry, developing drugs that can compete directly with Claritas Pharmaceuticals' offerings.
Merck
MRK
Mkt Cap366B
Merck produces a wide range of pharmaceutical products that could compete in the same therapeutic areas as Claritas Pharmaceuticals.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division, develops medications that may overlap with the treatments offered by Claritas Pharmaceuticals.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline focuses on a broad portfolio of drugs, potentially competing in the same niche as Claritas Pharmaceuticals.
Novartis
NVS
Mkt Cap292.35B
Novartis is known for its innovative medicines and could have competing products in the same categories as Claritas Pharmaceuticals.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie operates in similar therapeutic areas and could have drugs that compete with those of Claritas Pharmaceuticals.
AMGEN
AMGN
Mkt Cap233.78B
Amgen, a biotech firm, develops therapies that might directly compete with Claritas Pharmaceuticals' biopharmaceutical products.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb offers a range of prescription medicines that could directly compete with Claritas Pharmaceuticals.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company develops drugs that could be in direct competition with the treatments developed by Claritas Pharmaceuticals.
Sanofi
SNY
Mkt Cap107.39B
Sanofi produces a variety of pharmaceutical products that could compete across several of the same therapeutic areas as Claritas Pharmaceuticals.

About

CLARITAS PHARMACICLS INC
Show more...
CEO
Robert Farrell
Employees
3
Country
Canada
ISIN
CA48349P1036

Listings

STU
DE
S6V4.STU
OTC Link
US
CLAZF

0 Comments

Share your thoughts

FAQ

What is Kalytera Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Kalytera Therapeutics stocks are traded under the ticker S6V4.STU.
What is Kalytera Therapeutics revenue for the last year?▼
Kalytera Therapeutics revenue for the last year amounts to 0 EUR.
What is Kalytera Therapeutics net income for the last year?▼
S6V4.STU net income for the last year is 4.05M EUR.
How many employees does Kalytera Therapeutics have?▼
As of September 04, 2026, the company has 3 employees.
In which sector is Kalytera Therapeutics located?▼
Kalytera Therapeutics operates in the Health & Wellness sector.
When did Kalytera Therapeutics complete a stock split?▼
Kalytera Therapeutics has not had any recent stock splits.
Where is Kalytera Therapeutics headquartered?▼
Kalytera Therapeutics is headquartered in San Rafael, Canada.